Clinical Trials Logo
  1. Home
  2. Nonsmall Cell Lung Cancer
  3. NCT02951611

Effects of Acupuncture Stimulation on Systemic Inflammation

Nonsmall Cell Lung Cancer Clinical Trial

Official title:
Effects of Acupuncture Stimulation on Systemic Inflammation in Patients Undergoing Video-assisted Thoracoscopic Lobectomy Surgery

Clinical Trial Summary

60 ASA physical status I or II patients, aged 18-75 years old , scheduled for elective video-assisted thoracoscopic lobectomy surgery,will be randomized into 2 groups,with 30 patients in each group: 1. control group and 2. treatment group. Patients in treatment group will receive transcutaneous electrical acupoint stimulation(TEAS) during the surgery and at 6h and 24h after surgery. Patients in the control group received only TIVA general anesthesia and sham electrical stimulation. Serum from patients of both groups will be collected at before surgery, 1h and 25h after surgery, respectively. Serum levels of TNF-alpha, IL-1 beta, CXCL8, IFN gamma and IL-4 at different time points will be measured and compared between the two groups.

Clinical Trial Description

60 ASA physical status I or II patients, aged 18-75 years old , scheduled for elective video-assisted thoracoscopic lobectomy surgery,will be randomized into 2 groups,with 30 patients in each group: 1. control group, who will receive total intravenous anesthesia(TIVA) and sham stimulation; and 2. treatment group, who will receive (TIVA) and transcutaneous electrical acupoint stimulation(TEAS). Since 30 min before induction of anesthesia, patients in treatment group will be stimulated at the 4 acupoints , Houxi、Zhigou、Neiguan and Hegu on both sides by Han's Acupoint Nerve Stimulator(HANS) until the end of the operation. At 6h and 24h after surgery, patients in treatment group will receive TEAS again, for 30 min each time.The frequency was 2/100Hz,the stimulate intensity was the maximum current that could be tolerated when the patients were awake.The control group received only TIVA general anesthesia and sham electrical stimulation.Serum from patients of both groups will be collected at before surgery, 1h and 25h after surgery, respectively and serum levels of TNF-alpha, IL-1 beta, CXCL8, IFN gamma and IL-4 at different time points will be measured. The primary outcome measures are serum TNF-alpha and IL-1 beta levels at 25h after surgery. The secondary outcome measures include serum levels of TNF-alpha, IL-1 beta, CXCL8, Th1/Th2 ratio (by calculating IFN gamma/IL-4) at 1h post surgery and serum levels of CXCL8, Th1/Th2 ratio at 25h post surgery. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02951611
Study type Interventional
Source RenJi Hospital
Contact Jie Tian, PhD,MD
Phone 86-21-68383702
Email vaseline2001@hotmail.com
Status Recruiting
Phase N/A
Start date November 2016
Completion date June 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06147570 - A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Phase 2
Recruiting NCT01312337 - Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT05860582 - A Study of [14C]GB491 in Male Healthy Subjects Phase 1
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT02562027 - SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer N/A
Recruiting NCT05358249 - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2
Active, not recruiting NCT02954523 - Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Phase 1/Phase 2
Terminated NCT03998189 - Metabolic and Microbial Profiling of Lung Cancer N/A
Not yet recruiting NCT03258671 - IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer N/A
Recruiting NCT03838588 - The Tracking Molecular Evolution for NSCLC (T-MENC) Study
Active, not recruiting NCT04984811 - NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Phase 2
Recruiting NCT05688280 - Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS Phase 1/Phase 2
Recruiting NCT02974933 - Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Phase 2
Active, not recruiting NCT02980536 - cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China
Completed NCT02972216 - Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Phase 4
Recruiting NCT02905591 - A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC Phase 2
Recruiting NCT05873439 - Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC Early Phase 1
Active, not recruiting NCT02981108 - A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC Phase 1/Phase 2
Active, not recruiting NCT02299141 - Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT04900935 - Patient-centered, Optimal Integration of Survivorship and Palliative Care N/A